607-32-9Relevant articles and documents
Design, synthesis and biological evaluation of N1-(isoquinolin-5-yl)-N2-phenylpyrrolidine-1,2-dicarboxamide derivatives as potent TRPV1 antagonists
Gao, Mingxiang,Nie, Cunbin,Li, Jinyu,Song, Beibei,Cheng, Xinru,Sun, Erying,Yan, Lin,Qian, Hai
, p. 100 - 108 (2018/10/05)
Reported herein is the design, synthesis, and pharmacologic evaluation of a class of TRPV1 antagonists constructed on a N1-(isoquinolin-5-yl)-N2-phenylpyrrolidine-1,2-dicarboxamide platform that evolved from a 5-aminoisoquinoline urea lead. Advancing the SAR of this series led to the eventual identification of 3b, comprising a p-Br substituted phenyl. In a TRPV1 functional assay, using cells expressing recombinant human TRPV1 channels, 3b displayed potent antagonism activated by capsaicin (IC50 = 0.084 μM) and protons (IC50 = 0.313 μM). In the preliminary analgesic and body temperature tests, 3b exhibited good efficacy in capsaicin-induced and heat-induced pain models and without hyperthermia side-effect. On the basis of its superior profiles, 3b could be considered as the lead candidate for the further development of antinociceptive drugs.
One substrate, two modes of C-H functionalization: A metal-controlled site-selectivity switch in C-H arylation reactions
Tiwari, Virendra Kumar,Kamal, Neha,Kapur, Manmohan
supporting information, p. 262 - 265 (2017/11/27)
A unique site-selectivity switch has been achieved in the ruthenium-catalyzed C-H arylation reaction of N-acetyl-1,2-dihydroisoquinolines. This metal-mediated switch is antipodal to the previous report on the palladium-mediated C-4 C-H arylation on the same substrate. Mechanistic details reveal interesting aspects of the reaction pathway, and kinetic studies bring out the difference in the modes of C-H activation adopted by the two catalytic systems.
Synthesis of Carbamide Derivatives Bearing Tetrahydroisoquinoline Moieties and Biological Evaluation as Analgesia Drugs in Mice
Qiu, Qianqian,Wang, Jingjie,Deng, Xin,Qian, Hai,Lin, Haiyan,Huang, Wenlong
, p. 347 - 352 (2015/05/13)
Transient receptor potential vanilloid 1 (TRPV1) is a ligand-gated non-selective cation channel that is considered to be an important pain integrator. Tetrahydroisoquinoline, the prototypical antagonist of TRPV1, has a clear therapeutic potential. Here, a series of carbamide derivatives of tetrahydroisoquinoline were designed and synthesized. Preliminary biological tests suggested that the compounds I 1, I 2, and I 9 had favorable TRPV1 antagonism activity. In further studies, I 1 exhibited better antinociceptive activity than the positive control BCTC in diverse pain models. All of these results suggested that I 1 can be considered as the lead candidate for the further development of antinociceptive drugs. A novel carbamide derivative of tetrahydroisoquinoline I 1 had impressive TRPV1 antagonism activity (89.02%), exerting potency similarity with the positive control BCTC. Moreover, in mice, I 1 could significantly inhibit the reaction to pain and nociception in three different pain models, and trigger the analgesic activity in a dose-dependent manner.
